Physician profile
Zoya Preys
NPI 1306895156
$2,101.22
in general payments reported to CMS, 2019-2025
30 companies · $467 in 2025
The $467 reported for 2025 was more than what 79% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $272 · 2021: $351 · 2022: $274 · 2023: $91.00 · 2024: $113 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $392.20 | 2019-2022 | |
| Sage Therapeutics, LLC | $168.83 | 2025 | Zurzuvae |
| Avion Pharmaceuticals | $122.19 | 2019-2022 | |
| Therapeuticsmd, INC. | $110.15 | 2019-2021 | |
| Exeltis, USA INC. | $105.31 | 2022-2025 | Slynd |
| Hologic Sales and Service, LLC | $104.88 | 2019-2025 | Aptima, Acessa Provu System, Thinprep 2000 Processor |
| Astellas Pharma US INC | $104.60 | 2024-2025 | Veozah |
| Allergan, INC. | $101.79 | 2019-2020 | |
| Davol INC. | $89.51 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.28 | 2019 | |
| Medicem INC. | $69.39 | 2020-2021 | |
| Pfizer INC. | $63.24 | 2019-2022 | |
| Becton, Dickinson and Company | $58.76 | 2022-2023 | Bd Onclarity |
| Sumitomo Pharma America, INC. | $55.67 | 2025 | Myfembree |
| Supernus Pharmaceuticals, INC. | $45.43 | 2025 | Qelbree |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $44.65 | 2019-2024 | Paragard T 380a |
| Covidien LP | $41.25 | 2019 | |
| Amag Pharmaceuticals, INC. | $40.86 | 2019 | |
| Millicent US INC | $39.52 | 2025 | Femlyv, Intrarosa |
| Lupin INC. | $37.64 | 2019-2020 | |
| Baxter Healthcare | $35.74 | 2022 | |
| Minerva Surgical, INC | $30.36 | 2023 | |
| Alexion Pharmaceuticals, INC. | $29.00 | 2019 | |
| Organon LLC | $24.65 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $22.28 | 2023 | Vivjoa |
| Urovant Sciences INC | $20.80 | 2022 | |
| Merck Sharp & Dohme LLC | $18.25 | 2020 | |
| Genzyme Corporation | $17.62 | 2022 | |
| Dysis Medical, INC. | $17.45 | 2021 | |
| Evofem Biosciences, INC. | $14.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zoya Preys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.